甲狀腺疾病治療市場規模、佔有率和成長分析（按類型、藥物、給藥途徑、分銷管道和地區）- 2025-2032 年產業預測

2023 年甲狀腺疾病治療市場規模價值 26 億美元，預計將從 2024 年的 27 億美元成長到 2032 年的 37 億美元，預測期內（2025-2032 年）的複合年成長率為 4.0%。

由於人口老化導致甲狀腺功能亢進等疾病的發病率上升、醫療技術的進步以及對早期診斷和治療認知的提高，全球甲狀腺疾病治療市場正在經歷顯著成長。創新的個人化和標靶治療正在湧現，北美和歐洲由於疾病盛行率高和醫療支出高而成為主要市場。由於醫療保健基礎設施的改善和人們意識的提高，拉丁美洲和亞太地區的新興經濟體提供了巨大的成長機會。遠端醫療也變得越來越普遍，增加了患者獲得內分泌服務的機會。儘管存在診斷設施有限和治療費用高昂等挑戰，甲狀腺疾病治療市場的整體前景仍然樂觀，表明未來幾年將具有彈性並持續擴張。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究

甲狀腺疾病治療市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 甲狀腺機能低下症
• 甲狀腺功能亢進

甲狀腺疾病治療市場規模（按藥物類型和複合年成長率） (2025-2032)

• 市場概況
• 左旋甲狀腺素
• 三碘甲狀腺胺酸
• 丙硫氧嘧啶
• 咪唑化合物
• 其他

甲狀腺疾病治療市場規模（按給藥途徑和複合年成長率） (2025-2032)

• 市場概況
• 口服
• 靜脈
• 其他

甲狀腺疾病治療市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 批發的
• 零售商
• 網路藥局
• 其他

甲狀腺疾病治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• GSK Plc（UK）
• Merck KGaA（Germany）
• Viatris Inc.（USA）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Exelixis Inc.（USA）
• Abbott Laboratories（USA）
• Fresenius SE & Co. KGaA（Germany）
• Jerome Stevens Pharmaceuticals Inc.（USA）
• Lannett Co. Inc.（USA）

結論和建議

Thyroid Gland Disorders Treatment Market size was valued at USD 2.6 billion in 2023 and is poised to grow from USD 2.7 billion in 2024 to USD 3.7 billion by 2032, growing at a CAGR of 4.0% during the forecast period (2025-2032).

The global market for thyroid gland disorder treatments has seen remarkable growth due to the rising incidence of conditions like hyperthyroidism, driven by an aging population, advancements in medical technology, and heightened awareness of early diagnosis and treatment. Innovative personalized medicine and targeted therapies have emerged, positioning North America and Europe as key markets due to higher prevalence rates and healthcare expenditures. Emerging economies in Latin America and Asia-Pacific present significant growth opportunities, fueled by improved healthcare infrastructure and increased awareness. Telemedicine is also gaining traction, enhancing patient access to endocrinology services. Despite challenges such as limited diagnostic facilities and high treatment costs, the overall outlook for the thyroid disorder treatment market remains positive, suggesting resilience and continued expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Thyroid Gland Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Thyroid Gland Disorders Treatment Market Segments Analysis

Global Thyroid Gland Disorders Treatment Market is segmented by Type, Drug, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Hypothyroidism and Hyperthyroidism. Based on Drug, the market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based compounds and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Others. Based on Distribution Channel, the market is segmented into Wholesale Distribution, Retail Stores, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Thyroid Gland Disorders Treatment Market

The global prevalence of thyroid disorders, including hyperthyroidism, hypothyroidism, and various forms of thyroid cancer, is on the rise, largely due to increasing mental stress and changing lifestyle factors. Environmental influences have also contributed to the surge in these conditions, leading to a greater need for effective treatments. Consequently, the market for thyroid gland disorder treatments has expanded significantly to accommodate the growing patient population seeking specialized medical care for their conditions. This escalating demand is driving innovation and investment in therapeutic options, underscoring the importance of addressing thyroid health in today's world.

Restraints in the Thyroid Gland Disorders Treatment Market

The pricey nature of prescription medications significantly impacts patients undergoing long-term treatment for thyroid disorders, creating a considerable barrier. Therapeutic options, such as radioactive iodine therapy and surgical interventions, often incur substantial costs, which can be prohibitive for many individuals. This challenge is especially pronounced for those residing in regions with limited healthcare access or inadequate health insurance coverage, making these essential treatments a major financial strain. Consequently, the high expenses associated with thyroid gland disorder therapies can hinder patients from receiving timely and necessary medical attention, ultimately affecting their overall health and well-being.

Market Trends of the Thyroid Gland Disorders Treatment Market

The thyroid gland disorders treatment market is experiencing significant growth propelled by rising incidence rates worldwide. This trend has prompted pharmaceutical companies to intensify their research and development efforts, resulting in advanced treatment options that cater to an expanding patient population. Key market players are focused on innovation, striving to develop more effective and affordable therapies. These innovations not only aim to enhance overall patient outcomes but also prioritize minimizing side effects and improving quality of life. As a result, the market is poised for sustained growth, reflecting a proactive response to the increasing need for effective thyroid disorder management solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Thyroid Gland Disorders Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hypothyroidism
• Hyperthyroidism

Global Thyroid Gland Disorders Treatment Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based compounds
• Others

Global Thyroid Gland Disorders Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Others

Global Thyroid Gland Disorders Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Wholesale Distribution
• Retail Stores
• Online Pharmacy
• Others

Global Thyroid Gland Disorders Treatment Market Size & CAGR (2025-2032)

• North America (Type, Drug, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jerome Stevens Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations